Desvenlafaxine - Revision history

MDElliottMD: parser-claude: Desvenlafaxine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:17:52Z

parser-claude: Desvenlafaxine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:17, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Desvenlafaxine		\| generic = Desvenlafaxine (succinate)
	\| brand = Pristiq		\| brand = Pristiq
	\| structure =		\| structure =
	\| classes = SNRI, Antidepressant		\| classes = [[:Category:SNRIs\|Serotonin-norepinephrine reuptake inhibitor (SNRI)]], [[:Category:Antidepressants\|Antidepressant]]
	\| ~~mechanism~~ = ~~Serotonin–norepinephrine reuptake inhibitor~~		\| uses = <vote slug="major-depressive-disorder-use">Major depressive disorder (FDA)</vote>, <vote slug="menopausal-vasomotor-use">Menopausal vasomotor symptoms (off-label)</vote>, <vote slug="neuropathic-pain-broad-use">Neuropathic pain (off-label)</vote>
	\| ~~uses~~ =		\| starting_dose = 50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine)
	\| ~~starting_dose~~ =		\| preparations = ER tablets 25, 50, 100 mg
	\| ~~preparations~~ =		\| fda_max = 50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available)
	\| ~~fda_max~~ =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Antidepressant effect emerges over 1-2 weeks
	\| duration =		\| duration = 24 hours
	\| halflife =		\| halflife = ~11 hours<ref name="pristiq-label">FDA Prescribing Information, Pristiq (desvenlafaxine succinate), Pfizer/Wyeth, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021992s048lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~80% (oral)<ref name="pristiq-label" />
	~~\| pregnancy~~ =		\| pregnancy = Observational signal for neonatal adaptation syndrome with late-pregnancy exposure (SNRI class effect).{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults<ref name="pristiq-label" />
	\| ~~intro =~~		\| mechanism = <vote slug="desvenlafaxine-mech-claim">Serotonin and norepinephrine reuptake inhibitor. '''The active metabolite of venlafaxine''' formed by CYP2D6 O-demethylation, separately marketed as a parent compound to bypass the CYP2D6 activation step.</vote> The pharmacological advantage over venlafaxine: less inter-individual variability (no CYP2D6 genotype dependence for activation), fewer CYP-mediated interactions, and simpler 50 mg once-daily dosing without titration. The same SNRI-class concerns apply: severe discontinuation syndrome on abrupt stop (slow taper essential) and dose-dependent diastolic hypertension at higher doses<ref name="pristiq-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions = <pharmaInteractions~~/>
	\| ~~pregnancy_details =~~
	~~\| monitoring~~ =
	~~\| counseling~~ =
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:~~Serotonin–Norepinephrine Reuptake Inhibitors (~~SNRIs)]]		[[Category:SNRIs]]
	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:48Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)]]
	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:48Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:29Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:36Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Antidepressants]]		[[Category:Antidepressants]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Desvenlafaxine
+| generic            = Desvenlafaxine
-| brand             = Pristiq
+| brand              = Pristiq
-| classes           = SNRI, Antidepressant
+| structure          =
-| mechanism         = Serotonin–norepinephrine reuptake inhibitor
+| classes            = SNRI, Antidepressant
 }}
 [[Category:Antidepressants]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Desvenlafaxine
| brand = Pristiq
| classes = SNRI, Antidepressant
| mechanism = Serotonin–norepinephrine reuptake inhibitor
}}
[[Category:Antidepressants]]